ArticleJournal of tissue engineering and regenerative medicine2018
The productivity limit of manufacturing blood cell therapy in scalable stirred bioreactors.
Article in Journal of tissue engineering and regenerative medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Mechanotransduction mechanisms in human erythrocytes: Fundamental physiology and clinical significance.Channels (Austin, Tex.) · 2025Review
- Biosynthetic blood surrogates: Current status and future opportunities.Bioengineering & translational medicine · 2025Review
- A heterozygous CEBPA mutation disrupting the bZIP domain in a RUNX1 and SRSF2 mutational background causes MDS disease progression.Nature communications · 2025Article
- In vitro studies of human erythropoiesis using a 3D silk-based bone marrow model that generates erythroblastic islands.Blood advances · 2025Article
- Human serum albumin or polyvinyl alcohol can only partially replace human plasma during in vitro red cell production from PBMC.Scientific reports · 2025Article
- Progress in Development of Functional Biological and Synthetic Blood Products to Augment Transfusable Blood Supply in Operational Medicine.Bioengineering (Basel, Switzerland) · 2025Review
- Engineering synthetic signaling receptors to enable erythropoietin-free erythropoiesis.Nature communications · 2025Article
- Stem cell factor and erythropoietin-independent production of cultured reticulocytes.Haematologica · 2024Article
- Progresses in overcoming the limitations of in vitro erythropoiesis using human induced pluripotent stem cells.Stem cell research & therapy · 2024Review
- Current status of red blood cell manufacturing in 3D culture and bioreactors.Blood research · 2023Review
- Expansion and differentiation of ex vivo cultured erythroblasts in scalable stirred bioreactors.Biotechnology and bioengineering · 2022Article
- The use of pluripotent stem cells to generate diagnostic tools for transfusion medicine.Blood · 2022Article
- Selection of O-negative induced pluripotent stem cell clones for high-density red blood cell production in a scalable perfusion bioreactor system.Cell proliferation · 2022Article
- Arsenite exposure inhibits the erythroid differentiation of human hematopoietic progenitor CD34Scientific reports · 2021Article
- Industrially Compatible Transfusable iPSC-Derived RBCs: Progress, Challenges and Prospective Solutions.International journal of molecular sciences · 2021Review
- Latest culture techniques: cracking the secrets of bone marrow to mass-produce erythrocytes and plateletsHaematologica · 2021Review
- A Scalable Suspension Platform for Generating High-Density Cultures of Universal Red Blood Cells from Human Induced Pluripotent Stem Cells.Stem cell reports · 2021Article
- Differentiation of human induced pluripotent stem cells into erythroid cells.Stem cell research & therapy · 2020Review
- Purifying stem cell-derived red blood cells: a high-throughput label-free downstream processing strategy based on microfluidic spiral inertial separation and membrane filtration.Biotechnology and bioengineering · 2020Article
- Induced Pluripotent Stem Cell-Derived Red Blood Cells, Megakaryocytes, and Platelets: Progress and Challenges.Current stem cell reports · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Manufacture of red blood cells (RBCs) from progenitors has been proposed as a method to reduce reliance on donors. Such a process would need to be extremely efficient for economic viability given a relatively low value product and high (2 × 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.